Wedbush initiates General Fusion stock with neutral rating at $7

Wedbush initiated coverage of General Fusion with a Neutral rating and a $7.00 price target, versus a current share price of $6.09; the stock is down 43% over the past year. The company has approximately $150 million in cash, which it says will fund Lawson Machine 26 milestones through 2028, but not a first-of-a-kind plant targeted for the mid-2030s. Wedbush cites potential exposure to a $1 trillion-plus fusion market by 2050, while InvestingPro’s Fair Value assessment suggests shares may be overvalued.

Analysis

The key distinction is between technical de-risking and commercial de-risking. Hitting intermediate plasma milestones could improve financing access and the value of the option, but even meeting the Lawson criterion would not establish net-electric output, plant economics, reliability, or a bankable route to deployment. The 2050 market estimate therefore has little near-term earnings relevance; treating capital deployed as a valuation anchor risks confusing R&D spend with recoverable asset value.

Over the next 1–3 months, the initiation and its $7 target are unlikely to resolve the central question: whether the company can reach successive milestones without needing capital before the stated runway ends. The more consequential path is through 2028, when each technical result may change the probability of follow-on funding; a first plant remains a much longer-dated and separately financed undertaking. High redemptions in the transaction are a caution about investor demand, not proof of future financing failure.

Contrarian angle: the near-term threat to conventional nuclear, gas, renewables, or storage is negligible; fusion is not yet a substitute for dispatchable capacity. Conversely, a successful milestone can re-rate the equity before commercial viability, so a purely dismissive stance may miss option value. No direct trade is justified from this information alone. Watch cash burn, remaining runway, milestone definitions and independent verification, plus any financing terms. Thesis weakens if milestones slip, cash runway contracts materially, or results fail to demonstrate progress beyond headline plasma conditions.

Key Decisions for Investors

• Avoid treating the $1 trillion-plus long-term market estimate or capital already deployed as evidence of present commercial value; do not initiate a direct position solely on the coverage note.
• Set an event-driven watch through 2028: verify milestone timing and independent technical evidence, and track quarterly cash use against management’s stated funding runway. A material acceleration in burn or a milestone delay would raise dilution risk and weaken the thesis.
• Keep conventional power exposures separate from fusion optionality: no near-term short in gas, fission, renewables, or storage is warranted on this news, since there is no demonstrated commercial substitution mechanism.
• Reassess only if the company shows independently verifiable technical progress and provides credible evidence on net-energy performance, plant economics, and financing beyond the current program; failure on those measures would falsify the re-rating case.